AER 1506932 is a spontaneous case received on 10/Dec/2014 from a physician via a company representative and 
concerns a female patient of unspecified age  who developed epilepsy and suspicion of progressive multifocal 
leukoencephalopathy while being treated with bevacizumab (Avastin).
No medical history, concurrent condition, concomitant medication or past drugs were reported.
On an unspecified date, the patient started therapy with bevacizumab infusion (route, dose. frequency were not 
reported) for ovarian cancer. She was treated with bevacizumab in maintenance. Later, she developed epilepsy and
suspicion of progressive multifocal leukoencephalopathy and was hospitalized in the intensive care unit.
At the time of this report, the outcome of the events epilepsy and suspicion of progressive multifocal 
leukoencephalopathy was unknown and it was also unknown whether the therapy with bevacizumab was ongoing 
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 191 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
or not.
The physician assessed epilepsy and suspicion of progressive multifocal leukoencephalopathy as life threatening 
but did not provide the causality with bevacizumab.
The French imputability for bevacizumab concerning the events epilepsy and suspicion of progressive multifocal 
leukoencephalopathy  is C1 S1 I1. 
Further information has been requested.